Daré Bioscience announced its Q1 2026 financial results, highlighting a second positive interim review of its Ovaprene Phase 3 trial, a potential first FDA-approved hormone-free monthly contraceptive. The company plans to start dispensing its DARE to PLAY sildenafil cream and launch Flora Sync LF5 vaginal probiotic in summer 2026, expecting first product revenues by June. Daré is advancing multiple women’s health products with clinical backing and aims to diversify revenue streams through product sales alongside grants and equity financing. Enrollment for Ovaprene’s trial is expected to complete in 2026, with primary endpoint analysis anticipated in 2027.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
